These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37861553)

  • 1. A prognostic and immunotherapy effectiveness model for pancreatic adenocarcinoma based on cuproptosis-related lncRNAs signature.
    Zhang N; Yu X; Sun H; Zhao Y; Wu J; Liu G
    Medicine (Baltimore); 2023 Oct; 102(42):e35167. PubMed ID: 37861553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
    Wang S; Bai H; Fei S; Miao B
    Biochem Genet; 2024 Jun; 62(3):2332-2351. PubMed ID: 37898914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
    Huang Y; Gong P; Su L; Zhang M
    Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and validation of cuproptosis-related lncRNAs associated with pancreatic cancer immune microenvironment based on single-cell.
    Sun Y; Yao L; Man C; Gao Z; He R; Fan Y
    Front Immunol; 2023; 14():1220760. PubMed ID: 37822927
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cuproptosis-related lncRNA predict prognosis and immune response of lung adenocarcinoma.
    Wang F; Lin H; Su Q; Li C
    World J Surg Oncol; 2022 Sep; 20(1):275. PubMed ID: 36050740
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A cuproptosis-related lncRNA signature for predicting prognosis and immunotherapy response of lung adenocarcinoma.
    Yu S; Tang L; Zhang Q; Li W; Yao S; Cai Y; Cheng H
    Hereditas; 2023 Jul; 160(1):31. PubMed ID: 37482612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
    Zhang X; Ye Z; Xiao G; He T
    Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of a prognostic signature for lung adenocarcinoma using cuproptosis-related lncRNAs.
    Yalimaimaiti S; Liang X; Zhao H; Dou H; Liu W; Yang Y; Ning L
    BMC Bioinformatics; 2023 Mar; 24(1):81. PubMed ID: 36879187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and immune microenvironment analysis of cuproptosis-related LncRNAs in breast cancer.
    Pan Y; Zhang Q; Zhang H; Kong F
    Funct Integr Genomics; 2023 Jan; 23(1):38. PubMed ID: 36640225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
    Liu Y; Jiang J
    Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cuproptosis-Related lncRNA Gene Signature Establishes a Prognostic Model of Gastric Adenocarcinoma and Evaluate the Effect of Antineoplastic Drugs.
    Tu H; Zhang Q; Xue L; Bao J
    Genes (Basel); 2022 Nov; 13(12):. PubMed ID: 36553481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel cuproptosis-related lncRNA signature predicts the prognosis and immune landscape in bladder cancer.
    Bai Y; Zhang Q; Liu F; Quan J
    Front Immunol; 2022; 13():1027449. PubMed ID: 36451815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and Validation of Cuproptosis-Related LncRNA Signatures in the Prognosis and Immunotherapy of Clear Cell Renal Cell Carcinoma Using Machine Learning.
    Bai Z; Lu J; Chen A; Zheng X; Wu M; Tan Z; Xie J
    Biomolecules; 2022 Dec; 12(12):. PubMed ID: 36551318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel defined risk signature of cuproptosis-related long non-coding RNA for predicting prognosis, immune infiltration, and immunotherapy response in lung adenocarcinoma.
    Ma C; Li F; Gu Z; Yang Y; Qi Y
    Front Pharmacol; 2023; 14():1146840. PubMed ID: 37670938
    [No Abstract]   [Full Text] [Related]  

  • 15. Cuproptosis-related lncRNA signature for prognostic prediction in patients with acute myeloid leukemia.
    Zhu Y; He J; Li Z; Yang W
    BMC Bioinformatics; 2023 Feb; 24(1):37. PubMed ID: 36737692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crosstalk between copper homeostasis and cuproptosis reveals a lncRNA signature to prognosis prediction, immunotherapy personalization, and agent selection for patients with lung adenocarcinoma.
    Ma C; Gu Z; Ding W; Li F; Yang Y
    Aging (Albany NY); 2023 Nov; 15(22):13504-13541. PubMed ID: 38011277
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Construction of a Prognostic Model Based on Cuproptosis-Related lncRNA Signatures in Pancreatic Cancer.
    Jiang W; Du Y; Zhang W; Zhou W
    Can J Gastroenterol Hepatol; 2022; 2022():4661929. PubMed ID: 36406148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive analysis of cuproptosis-related lncRNAs signature to predict prognosis in bladder urothelial carcinoma.
    Zhu S; Li H; Fan Y; Tang C
    BMC Urol; 2023 Jul; 23(1):124. PubMed ID: 37479989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of prognosis, immune infiltration, and personalized treatment of hepatocellular carcinoma by analysis of cuproptosis-related long noncoding RNAs and verification
    Li S; Zhu Z; Lu J; Cao W; Song F; Xiao C; Zhang P; He Z; Weng J; Xu J
    Front Oncol; 2023; 13():1159126. PubMed ID: 37746284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic prediction of head and neck squamous cell carcinoma: Construction of cuproptosis-related long non-coding RNA signature.
    Huang Q; You Q; Zhu N; Wu Z; Xiang Z; Wu K; Ren J; Gui Y
    J Clin Lab Anal; 2022 Nov; 36(11):e24723. PubMed ID: 36189780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.